IFX-501

IFX-501 is a preclinical-stage monoclonal antibody being developed by Infinimmune, a biotechnology company specializing in the discovery of fully human antibodies from individuals with exceptional immunity. The drug was identified using the company's proprietary platform, which sequences and functionalizes the immune repertoires of "elite responders" to find rare antibodies with therapeutic potential. While Infinimmune has indicated that its lead programs focus on infectious diseases—including a human antibody targeting *Staphylococcus aureus*—the specific target and indication for IFX-501 have not been formally disclosed in the company's public pipeline. The program represents the company's strategy of leveraging natural human immune responses to create highly effective and safe biologics.